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ABSTRACT
Benign uterine fibroids are common female genital tract tumors and if symptomatic often require extensive surgery. When 
tumors are multiple and large or unusually located, the operative treatment may lead to significant morbidity and compro-
mise quality of life. Recovery period after surgical treatment may be complicated by patient’s medical condition and wound 
healing problems. Currently used other non-surgical treatment modalities usually provide only a temporal symptoms relief 
and may not be efficient in all affected women. In the last decade, minimally invasive treatment of uterine fibroids called 
Magnetic Resonance guided High-Intensity Focused Ultrasound (MRI HIFU) was introduced.  This technique uses thermal 
ablation simultaneously with MRI imaging of the mass and tissue temperature measurements during the procedure where 
a focused ultrasound beam is applied externally to destroy tumors located in the human body. Successful application of 
MRI HIFU has been recently described in patients with various malignancies, such as breast, prostate and hepatocellular 
cancers as well as soft tissue and bone tumors. This technique is innovative and has been proven to be safe and effective 
but there are several limitations for treatment. The article highlights the relative advantages and disadvantages of MRI 
guided HIFU in women with uterine fibroids. The authors also describe high-resolution MRI technique on 3T MRI, along 
with the approach to interpretation of HIFU results applied to uterine fibroids that has been experienced at one institution.
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INTRODUCTION
Uterine fibroids, or leiomyomas, are the most frequently 
found solid benign tumors of the female genital tract. Ap-
proximately 25 percent of women of childbearing age who 
have fibroids experience various symptoms such as pel-
vic pain, heavy menstrual bleeding as well as pregnancy 
complications [1]. Selection of other treatment options in 
women with uterine myomas depends on several condi-
tions, such as women’s age, parity, future reproductive plans 
and a willingness to preserve fertility. Also, the severity of 
accompanying symptoms such as pain and/or heavy bleed-
ing and as well as fibroids size, their number and location 
are considered important factors. Symptomatic fibroids 
are the most common indication for hysterectomy in the 
US and Europe [2]. An alternative option is myomectomy, 
indicated in cases of women who wish to preserve their 
fertility. It is important to note that as many as 27% of pa-
tients undergoing myomectomy may have recurrent fibroids 
within 10 years after surgery [3]. Several treatment options 
are now available for women with symptomatic uterine 
fibroids, ranging from surgical treatment such as hysterec-
tomy and myomectomy, to minimally invasive laparoscopic 
techniques, uterine arteries embolization (UAE) or medical 
therapy [4, 5]. In current clinical practice, uterus-conserving 
therapy is the standard of care for premenopausal patients 
with localized myomas. Laparotomy or laparoscopic opera-
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tions used to remove uterine fibroids are not major gyneco-
logical surgeries, but still are both invasive and not free of 
complications [3]. Because of this, optimizing treatment of 
women with symptomatic uterine fibroids remains a major 
topic of interest with minimally invasive or non-invasive 
methods that have become attractive alternative for surgery. 
In women who wish to preserve their uterus and fertility 
myomectomy may be beneficial, in such cases laparoscopy 
whenever feasible is favored over laparotomy. Laparoscopic 
myomectomy and the increasing use of robotic technol-
ogy for endoscopic procedures could also improve patient 
outcomes, including decreased recovery time [6]. However, 
since UAE and MRI guided HIFU are newer techniques com-
pared to surgical myomectomy, it is likely that the increased 
provider experience coupled with technical innovations 
could result in significant improvement as these technolo-
gies mature [5–7].
Ultrasonography is currently the most commonly used 
imaging modality in obstetrics and gynecology, however, the 
potential of focused ultrasound beam energy for therapeutic 
use in women is less well known. Imaging with magnetic 
resonance was first used as a therapeutic guidance in early 
1990-ties for the treatment of brain tumors, especially to 
obtain maximal possible resection of low grade gliomas [8]. 
After more than three decades of research and techno-
logical development focused ultrasound beam energy has 
become available for a non-invasive ablative treatment of 
various benign and malignant lesions. Treatment of choice 
in selected benign tumors is attractive alternative, but the 
main potential of HIFU is related to non-invasive destruc-
tion of malignant masses [9]. The method can be used for 
a definitive treatment, i.e. tumor removal as well as for the 
debulking of a malignant lesion that would facilitate the 
use of other treatment modalities. MRI use may facilitate 
tumor margin assessment in such cases. Importantly, ther-
mal ablation of tissue within human body can be easily 
monitored with temperature measurements available on 
MRI-based thermometry. An example of a malignant tumor 
that can be well visualized with high resolution contrast MRI 
and treated with HIFU is breast cancer [10, 11]. HIFU was 
introduced into clinical practice in the past decade, and cur-
rently is an approved method of choice for selected women 
with large uterine myomas. In case of uterine fibroids both 
real time-ultrasound imaging and MRI have been used. An 
apparent advantage of the 3T MRI lies in the precision of 
showing the extent of a mass to be treated and which is 
used to guide the high energy focused ultrasound beam 
directly to the target tissue [12]. By careful placement of 
energy focus HIFU creates discrete areas of tissue necrosis 
that do not require surgical removal. Because of this HIFU 
has become an alternative non-invasive method of uterine 
fibroids treatment. In order to summarize current status 
of knowledge we performed PubMed database search for 
papers related to MRI guided HIFU treatment modality for 
uterine fibroids. The purpose of this paper is to present 
an update on the potential use of this treatment in women 
with symptomatic uterine fibroids and to share our own 
experience with this method applied in one institution. In 
this review the 3T MRI guided HIFU procedure will be de-
scribed, including a description of important physiological 
and technical details, indications, contraindications, com-
plications, and outcomes.
RATIONALE FOR MRI USE FOR GUIDED 
FOCUSED ULTRASOUND FIBROID ABLATION
Magnetic resonance imaging guided high intensity fo-
cused ultrasound procedures provide a relatively safe and 
feasible alternative to surgical resection for the treatment 
of women with symptomatic uterine myomas [7, 12]. The 
potential of high focused ultrasound energy  to interact 
with various tissues has been known for several years and 
the first MRI guided HIFU platform received United States 
FDA approval in 2004 [13]. This method is currently used 
more frequently than percutaneous microwave ablation. 
The results of both treatments are quite similar [14]. The 
therapeutic potential of HIFU is related to its ability to de-
liver high-energy doses that are localized deep within the 
human body without harming the surrounding tissue.
MRI guided HIFU uses constant magnetic resonance 
monitoring, heats the fibroid tissue in individual sonifi-
cations until the tissue is completely ablated [15]. Apart 
from this thermal destruction, many other and complex 
non-thermal effects of focused high-energy ultrasound 
beam directed to the tissue of internal organ are also im-
portant. Multiple acoustic and mechanical stimuli are related 
to microbubble generation and related phenomenon called 
cavitation, radiation pressure exerted by the mechanical 
force in the focal zones and finally acoustic streaming related 
to the induced by ultrasound beam fluid movements. In case 
of fibroids acoustic cavitation is less important as it only 
happens in microbubbles containing gas and these micro-
bubbles are typically generated in fluid containing tissues by 
acoustic pressure waves. High energy of focused ultrasound 
beam may cause not only oscillation of the bubbles but also 
may release abruptly a stored energy that produces shock 
wave [16]. The effects of cavitation are much less predictable 
than high temperature use for heating of the tissue and as 
a final effect the destruction of affected region with internal 
hemorrhage may be observed. Combination of heating ef-
fects with cavitation may be used for the enhancement of 
the destruction effects [12–14]. 
The intensity of targeted tumor volumes sonication with 
ultrasound beam varies between 500 and 20 000 W/square 
cm applied over 1 to 60 seconds [16]. Since cooling of the 
499
Tomasz Łoziński et al., MRI guided HIFU therapy
www. journals.viamedica.pl/ginekologia_polska
tissue is needed, shorter periods of sonication are preferred. 
The cooling period after each cycle of sonication should 
last until the temperature would return to the baseline, 
which will prevent a buildup of excessive heat in a surround-
ing, non-targeted tissue lying in the ultrasound beam path 
zone. The focal spot is visible on MRI thermometry which 
can measure actual target tissue temperature changes. MRI 
guidance enables precise and reproducible spatiotemporal 
control of ultrasound beam energy delivered to the tissue 
and when the goal is accomplished, the power level may 
be increased again to obtain irreversible tumor necrosis 
related to denaturation of proteins and disruption of fibroid 
microvasculature [9].
Treatment planning, monitoring tissue damage and 
final results evaluation in focused ultrasound tissue de-
struction area requires extremely accurate precision of 
imaging. MRI outperforms ultrasound and other imaging 
techniques when HIFU is considered. Contrast-enhanced 
T1-weighted and T-2 weighted imaging is typically em-
ployed, but non-perfused volume is not directly correlated 
with the amount of non-viable tumor tissue. Because of 
this the protocols of MRI imaging for HIFU procedure are 
constantly upgraded. The study of high-intensity focused 
ultrasound tissue effects is facilitated with 3-Tesla (3T) MRI 
scanning [12]. One advantage of 3T MRI over most com-
monly used 1,5 T scanners is an improved signal-to-noise 
ratio (SNR) due to greater spin polarization, which may be 
used in imaging studies to improve spatial and/or temporal 
resolution. Another potential advantage is better contrast, 
including an improved contrast-to-noise ratio (CNR) with 
new or more physiologically specific sources of contrast [16].
Until today, there have been only a few reports about 
serious complications after HIFU. Recently, Kim al. [17] re-
ported three cases of complications after US-guided HIFU 
ablation for huge uterine fibroids, including two cases of 
rapid increase in size of the fibroids and one case of heavy 
vaginal bleeding. Upon completion of thermoablation, the 
control MRI scan should indicate the lack of contrast in the 
target tissue. The goal of HIFU treatment is to induce shrink-
ing of a tissue mass, and because of this, a close to 100% 
destruction of the fibroid should not be expected and is not 
the purpose of this treatment [13].
PHYSICAL BASIS OF HIFU
The explanation of the physical basis of MRI guided HIFU 
procedure is presented in Figure 1.
Pretreatment fibroid signal intensity (SI) and nonper-
fused volume (NPV) immediately after MRI guided HIFU 
procedure independently predict fibroid size and/or volume 
reduction during 12 month-follow up [16]. Published data 
indicate, that typical values of 11–13% reduction of an ini-
tial fibroid volume are most commonly expected [11, 13]. 
Moreover, most fibroids with estimated NPV less than 20% 
showed no further decrease in size after 12 months of fol-
low up [18]. Since the complete remission of a fibroid is not 
an ultimate goal of the treatment, in many countries this 
option is performed in the diagnostic and interventional 
radiology units and is offered mainly for the decrease of the 
size and symptoms relief [16].
First MRI guided HIFU unit in Poland has been installed 
in Pro Familia Hospital, Rzeszow within the Department of 
Gynecology in December, 2014 [12]. The Sonalleve 3T MRI 
guided HIFU platform was manufactured by Phillips (The 
Netherlands) uses a focused transducer to bundle ultra-
sound energy into a small volume at the target locations 
inside the human body. Patients before therapy need some 
Figure 1. A diagram presenting physical basis of HIFU treatment
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preparation that includes bladder or rectum fluid filling 
in order to obtain optimal ultrasound beam window [18]. 
 The Sonalleve 3T MRI system is designed for an intact skin. 
A typical placement of a patient for MRI guided HIFU pro-
cedure is shown on Figure 2.
During treatment, the ultrasound energy beam passes 
through the intact skin and soft tissue, causing localized 
high temperatures (60–100ºC) only in the focus area [13]. 
The skin and intermediate tissue are left unharmed. Within 
a few seconds high-intensity focused ultrasound beam 
produces a well-defined region of coagulative necrosis. Si-
multaneously used three-dimensional 3T MR images show 
immediate anatomical site reference data for treatment 
planning. During ablation procedure real-time temperature 
sensitive images are acquired and provide real-time infor-
mation on treatment progress Constant monitoring of all 
critical anatomical structures is feasible [19]. Figure 3 pres-
ents a typical example of a real-time 3T MR mapping of 
temperature changes within and around ablated tissue.
The unit acquires T2 signal intensity (SI) measurements 
which will be next used as classification parameters for 
determining patient suitability for the procedure. A visual 
inspection and SI values are used to classify fibroids into 
one of three types: type I (i.e. SI lower than that of skeletal 
muscles), type II (i.e. SI lower than that of myometrium but 
higher than that of skeletal muscles or type III (i.e. SI higher 
than that of the myometrium). The use of this classifica-
tion suggested that low T2 SI values might be predictive 
of high nonperfused volume (NPV) ratio [9]. Several other 
technical details related to MRI guided HIFU technique are 
presented below.
VOLUMETRIC HEATING
The focused ultrasound beam is rapidly transmitted over 
the tissue volume that was planned to be ablated. Ellipsoidal 
ablation volumes can be adjusted for the distances up to 
16 mm wide and 40 mm long, leading to a macroscopic 
ablation of this tissue zone within seconds. Larger target 
volumes are usually covered with multiple heating episodes 
repeated over time. This is opposite to uterine artery em-
bolization, where the effect is very fast and usually causes 
many suddenly appearing, unwanted side-effects [5, 9, 10].
REAL-TIME FEEDBACK
During treatment, the MRI scanner acquires tempera-
ture-sensitive images to monitor local heat distribution and 
to identify critical structures that must not be subjected to 
heat. The temperature information is used to automatically 
enhance HIFU delivery parameters, thus creating a feedback 
loop based on real-time temperature monitoring. This is 
an essential step extremely important to keep treatment 
times short while maintaining high-quality ablation of a tar-
get tissue [19]. 
HOMOGENEOUS HEATING
With a real-time feedback the 3T MRI guided HIFU sys-
tem constantly compensates released energy for local vari-
ations in tissue properties, such as inhomogeneous absorp-
tion, attenuation, perfusion, and diffusion [13]. Otherwise, 
these variations can lead to local overheating or insufficient 
heating. While overheating could pose undesired effects and 
in addition would lead to increased treatment time, insuf-
ficient heating, e.g. near cooling vessels, could potentially 
leave tissue unablated. Examples of 3T MR images of fibroids 
before and after MRI guided HIFU procedure are shown on 
Figures 4–6. Examples of typical changes in uterine myoma 
after HIFU therapy are shown on Figure 7.
It is important to emphasize that not all women with 
symptomatic fibroids may be treated with MRI guided HIFU 
method. Patients who may benefit from this treatment mo-
dality have to be carefully selected [15, 16]. Currently used 
qualification criteria for the procedure in our hospital in-
clude the following indications:
Figure 2. Patient positioning during treatment with 3T MRI guided 
HIFU Platform in Pro-Familia Hospital 
Figure 3. An example of 3T MRI real-time mapping of tissue 
temperature with yellow color depicting hot areas and blue color 
designated for colder areas
Ultrasound 
transductor
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 Ū large and symptomatic fibroids,
 Ū maximum size of the tumor < 130 mm,
 Ū positive qualification for the MRI/US scan, i.e. the 
presence of a suitable therapeutic window for ul-
trasound beam.
Exclusion criteria include: 
 Ū size of a mass larger > 130 mm (relative, case-by-case 
decision),
 Ū atypical localization of a fibroid(s),
 Ū pregnancy,
 Ū pelvic inflammatory disease (PID),
 Ū contraindications to MRI exam,
 Ū too close distance to the sacral bone < 20 mm.
SIDE EFFECTS/COMPLICATIONS OF  
MRI GUIDED HIFU THERAPY
There are several rare, but important side effects and 
complications related to MRI guided HIFU treatment which 
include:
 Ū pain,
 Ū inflammation of subcutaneous fatty tissue and mus-
cles of the abdominal wall,
 Ū skin burns,
 Ū deep vein thrombosis,
 Ū paresthesia of the leg due to the nerve irritation 
or damage,
 Ū bowel perforation (extremely rare).
Figure 4. An example of 3T MRI image of a fibroid before treatment
Figure 5. Treatment with 3T MRI guided HIFU 
visualization of a catheter manouvering in the urinary 
bladder 
Figure 6. 3T MRI image of a fibroid following 
successful MRI guided HIFU treatment. A round 
shape black region corresponds to the area of tissue 
ablation in the fibroid
Figure 7. A typical sonographic appearance of a fibroid before 3T MRI guided HIFU therapy (A) and after 3 (B) and 6 months (C) of follow-up 
A B C
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It is important to present a detailed information on the 
whole procedure to the woman considered for a potential 
MRI guided HIFU treatment. When agreeing for this pro-
cedure, the patient should know and understand not only 
basic information but also the expected effectiveness, the 
possible side-effects and the length of the procedure. This 
has been recently reported to be as long as the median of 
92 minutes with the range between 54 to 121 minutes [16]. 
Knowledge on all these issues seems to be crucial for further 
patient’s satisfaction rate with the procedure itself. It is im-
portant to inform the patient that following MRI guided HIFU 
treatment occasionally some tissue components may be 
discharged vaginally, also an increased uterine bleeding may 
continue until approximately 3 months after the procedure.
Following 3 years of the 3T MRI guided HIFU procedure 
application our initial results indicate that in 56% cases 
the effect of therapy revealed more than 70% of fibroid 
tissue ablation, which is similar to the results reported by 
other centers [7, 14, 15, 17, 18]. The most common causes 
of the withdrawal from treatment attempts were largely 
related to bowel location in relation to the fibroid position. 
In such cases repositioning of the fibroid required some 
maneuvering and was not always effective. The same type 
of complication was observed by other authors [7, 15, 18]. In 
2015 Pron [20] presented a meta-analysis of available studies 
on the use of MRI guided HIFU. The review included data 
on approximately 1600 women treated in 45 cohort studies, 
19 case reports and two systematic reviews. Overall reported 
complications rate was 1.6%, whereas the eligibility for the 
procedure was ranging from 14% to 75%. According to this 
review, in clinical studies the higher retreatment rates were 
generally found and immediate acute interventions follow-
ing the procedure were very rare. However, in most of these 
studies the follow-up was usually less than one year [20]. 
MRI guided HIFU should be performed only at hospitals or 
clinics possessing the requisite expertise and experience 
with this therapy. The experience should also include the 
ability to treat non-surgical and surgical side effects as well 
as typical complications. In addition, these centers should 
have an option to initiate appropriate post-interventional 
pain management [16].
The data on the long-term impact of HIFU therapy on fer-
tility are still insufficient, but recent report by Zhou et al. [21] 
has shown promising results. These Authors investigated 
pregnancy outcomes following the HIFU treatment in one 
institution over 5 years. In total 78 patients had 80 pregnan-
cies, in which 76 cases were natural pregnancies and four 
were obtained after IVF. The average time from treatment 
to pregnancy was 5.6 ± 2.7 months. There were no signifi-
cant complications in fetal development, uterine rupture, 
perinatal or postpartum complications. Pregnancies ended 
with 15 full term vaginal deliveries and 53 cesarean sec-
tions at term with 3 preterm cesarean sections. The Authors 
have concluded that HIFU can effectively treat women with 
uterine fibroids and can significantly reduce the time from 
treatment to pregnancy.
The cost-effectiveness of standard therapy in women 
with uterine fibroids depends on many factors that has to 
be taken into account. These costs include surgery, hospital 
admissions, outpatient visits, and medications and -what is 
often forgotten-medical treatment of women who became 
pregnant while having uterine fibroids. In addition to all 
these factors, there is a substantial cost of medical non-surgi-
cal treatment related to symptomatic uterine fibroids. It has 
been estimated  that the total direct cost of uterine fibroids 
treatment in the United States between $5.9–34.4 billion 
annually [22]. Recently, Cain-Nielsen at al. [23] presented 
updated cost-effectiveness analysis of three different treat-
ment modalities used in women with symptomatic uterine 
fibroids. When incorporating productivity costs, MRI guided 
HIFU incurred a mean cost of US$21, 232; myomectomy 
US$22,599; and UAE US$22,819. The difference in effective-
ness between the three treatments was minimal, but when 
the productivity costs were incorporated into this analysis, 
the MRI guided HIFU strategy became a cost-effective al-
ternative to myomectomy. The main advantage was the 
reduction in missed days of work from shorter postopera-
tive recovery. UAE remained dominated with and without 
lost productivity costs [23]. The impact of various modern 
treatment modalities such as UAE and MRI HIFU on fertility 
outcomes remains understudied. Although the cost of MRI 
guided high energy focused ultrasound is high, it can be 
offset by the elimination of the need for an operating room, 
the absence of expensive hospitalization and anesthesia, 
and a reduced complication rate. Additional research is 
needed to effectively use these important outcomes in 
future analyses. 
SUMMARY
In summary, 3T MRI guided HIFU is a unique, noninvasive 
uterine-preserving new treatment modality and as of today 
is no longer considered investigational for symptomatic 
uterine fibroids. This method is an alternative to hysterec-
tomy for women with symptoms producing fibroids and for 
those who had ineffective medical therapy. The goal of the 
therapy using focused ultrasound should be the achieve-
ment of the largest possible non-perfused volume (NPV) 
of a tumor. To adequatly compare currently used non-inva-
sive, minimally invasive and surgical methods used for the 
treatment of women with symptomatic uterine fibroids 
more prospective and well designed studies are needed. 
These studies should primarily assess rates of short-term 
and long-term complications, occurrence of serious side 
effects like e.g. thromboembolism as well as the need for 
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myomectomy and hysterectomy at a later stage of life of 
treated women.
Clinical advantages: It is a non-invasive treatment with 
a low risk of complications, with durable resolution of fibroid 
related symptoms. Easy planning and treatment in selected 
patients, no damage to surrounding tissue.
Patient advantages: Fast, non-invasive therapy, per-
formed on an out-patient basis, procedure can be repeated 
if necessary.
Disadvantages: Costs of equipment and high drop-out 
rate. Not all women with symptomatic fibroids may be suc-
cessfully treated with MRI guided HIFU and a drop-out rates 
may be quite high. To diminish this rate, a much better 
knowledge among gynecologists is needed before patients 
qualification for a possible MRI guided HIFU procedure.
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